ALNY
Price
$159.89
Change
+$1.89 (+1.20%)
Updated
Nov 3 closing price
Capitalization
21.39B
106 days until earnings call
Intraday BUY SELL Signals
UTHR
Price
$601.32
Change
+$5.19 (+0.87%)
Updated
Nov 3 closing price
Capitalization
25.79B
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALNY vs UTHR

ALNY vs UTHR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALNY vs. UTHR commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and UTHR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALNY with price predictions
Nov 03, 2026

ALNY in downward trend: price dove below 50-day moving average on October 01, 2026

ALNY moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 38 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In 54 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 33 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.

The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

The Aroon Indicator for ALNY entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 219 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.800) is normal, around the industry mean (3.051). P/E Ratio (27.239) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (439.647).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for UTHR with price predictions
Nov 02, 2026

UTHR in upward trend: price rose above 50-day moving average on September 30, 2026

UTHR moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend. In 27 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on UTHR as a result. In 59 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.

The Moving Average Convergence Divergence (MACD) for UTHR just turned positive on September 30, 2026. Looking at past instances where UTHR's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.

The 10-day moving average for UTHR crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.

Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTHR advanced for three days, in 220 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

The Aroon Indicator entered an Uptrend today. In 186 of 266 cases where UTHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.

UTHR broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. UTHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.030) is normal, around the industry mean (8.179). P/E Ratio (19.891) is within average values for comparable stocks, (-0.806). Projected Growth (PEG Ratio) (2.205) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (7.418) is also within normal values, averaging (181.047).

FUNDAMENTALS RATINGS
ALNY vs UTHR: Fundamental Ratings
ALNY
UTHR
OUTLOOK RATING
1..100
6728
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
1008
SMR RATING
1..100
1448
PRICE GROWTH RATING
1..100
8641
P/E GROWTH RATING
1..100
9724
SEASONALITY SCORE
1..100
4550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

UTHR's Valuation (71) in the Pharmaceuticals Other industry is in the same range as ALNY (91) in the Biotechnology industry. This means that UTHR’s stock grew similarly to ALNY’s over the last 12 months.

UTHR's Profit vs Risk Rating (8) in the Pharmaceuticals Other industry is significantly better than the same rating for ALNY (100) in the Biotechnology industry. This means that UTHR’s stock grew significantly faster than ALNY’s over the last 12 months.

ALNY's SMR Rating (14) in the Biotechnology industry is somewhat better than the same rating for UTHR (48) in the Pharmaceuticals Other industry. This means that ALNY’s stock grew somewhat faster than UTHR’s over the last 12 months.

UTHR's Price Growth Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for ALNY (86) in the Biotechnology industry. This means that UTHR’s stock grew somewhat faster than ALNY’s over the last 12 months.

UTHR's P/E Growth Rating (24) in the Pharmaceuticals Other industry is significantly better than the same rating for ALNY (97) in the Biotechnology industry. This means that UTHR’s stock grew significantly faster than ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYUTHR
RSI
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 2 days ago
67%
Momentum
ODDS (%)
Bearish Trend 1 day ago
67%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 5 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
66%
Bullish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 20 days ago
73%
Bullish Trend 5 days ago
70%
Declines
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 7 days ago
60%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 2 days ago
58%
Aroon
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 2 days ago
70%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (ALNY: $159.89 vs. UTHR: $601.32)
Brand notoriety: ALNY and UTHR are both not notable
ALNY represents the Biotechnology, while UTHR is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALNY: 211% vs. UTHR: 93%
Market capitalization -- ALNY: $21.39B vs. UTHR: $25.79B
ALNY [@Biotechnology] is valued at $21.39B. UTHR’s [@Pharmaceuticals: Generic] market capitalization is $25.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.53B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Biotechnology] industry is $2.2B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green while UTHR’s FA Score has 2 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • UTHR’s FA Score: 2 green, 3 red.
According to our system of comparison, UTHR is a better buy in the long-term than ALNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 4 TA indicator(s) are bullish while UTHR’s TA Score has 6 bullish TA indicator(s).

  • ALNY’s TA Score: 4 bullish, 6 bearish.
  • UTHR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, UTHR is a better buy in the short-term than ALNY.

Price Growth

ALNY (@Biotechnology) experienced а -29.50% price change this week, while UTHR (@Pharmaceuticals: Generic) price change was +1.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.09%. For the same industry, the average monthly price growth was -12.05%, and the average quarterly price growth was -17.02%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.23%. For the same industry, the average monthly price growth was -7.21%, and the average quarterly price growth was +2.47%.

Reported Earning Dates

ALNY is expected to report earnings on Feb 18, 2027.

UTHR is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-2.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (-1.23% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
ALNY
Daily Signal:
Gain/Loss:
UTHR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

UTHR and

Correlation & Price change

A.I.dvisor indicates that over the last year, UTHR has been loosely correlated with MNKD. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if UTHR jumps, then MNKD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UTHR
1D Price
Change %
UTHR100%
+0.87%
MNKD - UTHR
38%
Loosely correlated
+2.19%
GERN - UTHR
37%
Loosely correlated
+0.10%
ALNY - UTHR
36%
Loosely correlated
+1.20%
CBIO - UTHR
36%
Loosely correlated
+1.16%
INSM - UTHR
35%
Loosely correlated
-4.46%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TRUG0.790.07
+9.75%
Trugolf Holdings Inc
AFCG3.090.10
+3.34%
Advanced Flower Capital Inc
NEO16.830.34
+2.06%
NeoGenomics
HBB32.64-0.27
-0.82%
Hamilton Beach Brands Holding Company
SAIL18.99-0.20
-1.04%
SailPoint Inc